Hormonal
GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, achieving 18-21% body weight reduction in clinical trials. They work by changing how your brain signals hunger and fullness, not just by making you feel full. This can be particularly helpful if you have struggled with dieting in the past. Combining the medication with behavioral therapy yields the best results.
Current knowledge links weight loss with GLP- 1 RAs to central effects in brain regions expressing the GLP- 1R, modifying food preferences, reducing appetite and food intake, and increasing satiety. ... semaglutide, was approved with weight loss of up to around 18% after 68 weeks shown in phase 3 development... tirzepatide... appears promising in obesity management with weight loss of up to around 21% after 72 weeks in phase 3
Why this rating
Based on Phase 3 clinical trials (STEP program, SURPASS) with large sample sizes.
Source
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner et al. · Aging Cell · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →